Matches in Wikidata for { <http://www.wikidata.org/entity/Q88626675> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q88626675 description "artículu científicu espublizáu en xunetu de 2018" @default.
- Q88626675 description "scientific article published on 01 July 2018" @default.
- Q88626675 description "wetenschappelijk artikel" @default.
- Q88626675 description "наукова стаття, опублікована в липні 2018" @default.
- Q88626675 name "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" @default.
- Q88626675 name "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" @default.
- Q88626675 type Item @default.
- Q88626675 label "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" @default.
- Q88626675 label "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" @default.
- Q88626675 prefLabel "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" @default.
- Q88626675 prefLabel "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" @default.
- Q88626675 P1433 Q88626675-F3A4A5F6-2885-49D3-A874-4BC8671E3454 @default.
- Q88626675 P1476 Q88626675-38FA6297-213A-4113-A12B-FA156D87A299 @default.
- Q88626675 P2093 Q88626675-0A6B73DF-F1DE-4BFD-BADC-6A721A0CD10D @default.
- Q88626675 P2093 Q88626675-21B138E7-F7D0-4843-8D9B-F53E4AB1EDDB @default.
- Q88626675 P2093 Q88626675-A3BF1279-022A-41A0-9107-1E05693DC2CE @default.
- Q88626675 P2093 Q88626675-BD88AAE3-414C-4F44-924D-B916E1252199 @default.
- Q88626675 P2093 Q88626675-D99B9E3F-B9C7-476C-B193-6C20F7908903 @default.
- Q88626675 P2093 Q88626675-E6647C9B-DF8C-454E-A2D3-5E511CA3E533 @default.
- Q88626675 P2093 Q88626675-E8D2C4AD-B90D-4BB8-9176-57F90A91F174 @default.
- Q88626675 P304 Q88626675-8AB1B1DB-E2EE-4542-8320-E718228CB077 @default.
- Q88626675 P31 Q88626675-DC51CF95-18BF-43D5-8EFC-9CED55BB2756 @default.
- Q88626675 P356 Q88626675-9AF1996A-F0BF-40B4-B5A8-0F4312C8D350 @default.
- Q88626675 P433 Q88626675-46A50B10-C0EA-47C0-BCBD-B570E65C6C90 @default.
- Q88626675 P478 Q88626675-6E7F9960-8A6E-4753-A49B-808401EC1FFF @default.
- Q88626675 P50 Q88626675-C1E9B476-BA10-4505-86CF-126E5D31842C @default.
- Q88626675 P50 Q88626675-E9D1A3A9-827F-4E1A-B616-D7BA015C6ABF @default.
- Q88626675 P577 Q88626675-B7F6B32D-68AA-462D-A91E-028EC84006D2 @default.
- Q88626675 P698 Q88626675-ED95B0B2-C658-4A61-8F5D-3E68C65C2672 @default.
- Q88626675 P921 Q88626675-9DB19D39-E023-410E-8B7A-6F6BD918383A @default.
- Q88626675 P356 QAD.0000000000001845 @default.
- Q88626675 P698 29746295 @default.
- Q88626675 P1433 Q4651863 @default.
- Q88626675 P1476 "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" @default.
- Q88626675 P2093 "Andrew Hill" @default.
- Q88626675 P2093 "Charles Flexner" @default.
- Q88626675 P2093 "David Ripin" @default.
- Q88626675 P2093 "Francois Venter" @default.
- Q88626675 P2093 "Meg Doherty" @default.
- Q88626675 P2093 "Paul L Domanico" @default.
- Q88626675 P2093 "Polly Clayden" @default.
- Q88626675 P304 "1551-1561" @default.
- Q88626675 P31 Q13442814 @default.
- Q88626675 P356 "10.1097/QAD.0000000000001845" @default.
- Q88626675 P433 "12" @default.
- Q88626675 P478 "32" @default.
- Q88626675 P50 Q87771393 @default.
- Q88626675 P50 Q90377447 @default.
- Q88626675 P577 "2018-07-01T00:00:00Z" @default.
- Q88626675 P698 "29746295" @default.
- Q88626675 P921 Q937224 @default.